6 Analysts Assess Amylyx Pharma: What You Need To Know
Across the recent three months, 6 analysts have shared their insights on Amylyx Pharma (NASDAQ:AMLX), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 2 | 0 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $6.33, a high estimate of $8.00, and a low estimate of $3.00. A decline of 1.09% from the prior average price target is evident in the current average.
Interpreting Analyst Ratings: A Closer Look
The standing of Amylyx Pharma among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $8.00 | $8.00 |
| Graig Suvannavejh | Mizuho | Lowers | Neutral | $3.00 | $4.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $8.00 | $8.00 |
| Joel Beatty | Baird | Lowers | Neutral | $3.00 | $4.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $8.00 | - |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $8.00 | $8.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Amylyx Pharma. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Amylyx Pharma compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Amylyx Pharma's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Amylyx Pharma's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Amylyx Pharma analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About Amylyx Pharma
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
Financial Insights: Amylyx Pharma
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Amylyx Pharma displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 24.1%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -134.01%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Amylyx Pharma's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -31.35%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Amylyx Pharma's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -25.41%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
Analyst Ratings: What Are They?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.